For investors aiming to find stocks trading below their estimated true worth, a systematic screening process is necessary. One useful method is to select for firms that show a good fundamental valuation score, meaning they may be priced favorably compared to their financial numbers, while also holding satisfactory scores in profitability, financial soundness, and expansion. This technique tries to find possible chances where the market price might not completely represent the actual business caliber, a central idea of value investing. By demanding good fundamentals together with a low valuation, the approach tries to sidestep the typical "value trap," where an inexpensive stock is low-priced for a worsening cause.
One stock that recently appeared from such a "Decent Value" screen is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology firm dedicated to creating and selling treatments for rare genetic disorders. According to ChartMill's fundamental analysis report, BioMarin displays an interesting profile that matches the standards looked for by value-focused investors.
A Closer Look at the Valuation
The main attraction for any value investor is a good valuation, and BioMarin ranks well here with a ChartMill Valuation Rating of 8 out of 10. The report points out several numbers that imply the stock is trading at a lower price relative to both its field and its own future possibility:
- Industry-Relative Value: While BioMarin's standard Price/Earnings (P/E) ratio of 30.39 might seem high alone, it is viewed as "rather cheap" next to its biotechnology counterparts. The company is less expensive than 91.86% of the field based on this number. More forward-looking measures are even more interesting; its Price/Forward Earnings ratio of 12.37 positions it as less expensive than 97.48% of the field.
- Cash Flow and EBITDA Multiples: Valuation based on cash creation and operating earnings also looks positive. The company's Enterprise Value to EBITDA and Price/Free Cash Flow ratios are superior to about 96-97% of industry rivals.
- Growth Compensation: A low PEG ratio, which modifies the P/E ratio for projected earnings expansion, signals the market may not be entirely accounting for BioMarin's growth path. This is important for value investors, as it implies the lower price exists not due to poor outlook, but possibly because of market inattention or temporary feeling.
This mix of numbers is central for the value plan. It shows that an investor is not just buying a numerically inexpensive company, but one that is low-cost relative to its sector and its own expected growth, a possible indicator of being undervalued.
Assessing Financial Health and Profitability
A low valuation loses its charm if the company's base is unstable. So, the screening standards call for satisfactory scores in financial soundness and profitability to confirm business endurance. BioMarin performs here, with a Health Rating of 7 and a good Profitability Rating of 8.
The financial soundness evaluation shows a solid balance sheet:
- Strong Solvency: The company has an Altman-Z score of 5.48, showing low near-term bankruptcy danger and doing better than 73% of its field. Importantly, its Debt to Free Cash Flow ratio is a very good 0.83, meaning it could in theory pay off all debt with under a year's worth of cash flow.
- Sufficient Liquidity: With a Current Ratio of 5.21 and a Quick Ratio of 3.50, BioMarin has more than enough means to meet its short-term responsibilities easily.
On the profitability side, the company shows it can successfully turn revenue into earnings:
- Better Margins: BioMarin's Profit Margin of 10.83% and Operating Margin of 27.06% do better than over 91% and 94% of industry peers, in that order. Its Gross Margin of 81.43% also ranks well.
- Efficient Capital Use: The company's Return on Invested Capital (ROIC) of 9.64% is above its cost of capital and superior to 93.6% of peers, indicating it is generating value for shareholders.
For the value investor, these ratings are an important safeguard. They suggest that the company is not just numerically inexpensive but is a financially stable and profitable business, lowering the chance that the low price is a sign of basic deterioration.
Evaluating the Growth Trajectory
Pure value stocks occasionally lack growth, but the top chances frequently exist in companies where growth is being underrated. BioMarin's Growth Rating of 6 shows a varied history but a hopeful future, which is exactly the situation that can create opening.
- Past Performance: The company has shown good and steady revenue growth, averaging 11.60% each year over recent years. However, Earnings Per Share (EPS) has been changeable, showing drops on a trailing basis.
- Future Expectations: The story changes looking forward. Analysts predict a good speed-up, with EPS expected to increase by over 41% each year and revenue growth forecast to continue around 12%. The report mentions that EPS growth is "speeding up" from its past pattern.
This predicted speed-up is key. It supplies the possible trigger that value investors search for, a basic betterment that could lead the market to re-price the stock higher, narrowing the difference between its current price and its true value.
Conclusion and Investor Considerations
BioMarin Pharmaceutical Inc. displays a profile that fits a systematic value-seeking plan. It joins a good valuation relative to its field and growth outlook with the financial fortitude and profitability needed to endure doubt. The expected speed-up in earnings growth gives a believable basic trigger for a possible re-rating.
It is necessary to state that investing in biotechnology involves built-in dangers linked to clinical trials, regulatory approvals, and product sales. Also, while the screening standards are made to spotlight chances, they are not an assurance of future results.
Interested in examining other stocks that match this "Decent Value" profile? You can execute the same screen used to locate BioMarin to see a present list of qualifying companies. View the Decent Value Stocks screen here.
For a detailed look at all the fundamental numbers behind BioMarin's ratings, you can examine the full ChartMill Fundamental Analysis Report for BMRN.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consider their individual financial circumstances and risk tolerance before making any investment decisions.